New chikungunya vaccine enters first human safety trial
Vaccine
Not yet recruiting
This early-stage trial tests a new vaccine called PepGNP-ChikV, made from tiny synthetic particles, to see if it is safe and triggers an immune response against chikungunya virus. Forty healthy adults aged 18 to 60 will receive two doses 42 days apart. The study focuses on safety…
Early phase 1 • Sponsor: Gylden Pharma Ltd • Aim: Vaccine
Last updated Jun 27, 2026 12:24 UTC